Treatment options for BCG-unresponsive non–muscle-invasive bladder cancer: An updated review of the post-BCG therapeutic landscape
Non–muscle-invasive bladder cancer (NMIBC) constitutes the majority of urothelial carcinoma diagnoses; however, treatment failure following standard intravesical Bacillus Calmette–Guérin (BCG) immunotherapy remains a critical challenge in urologic oncology. Approximately 30–40% of patients experience recurrence, prompt...